Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Mini-Review Article

PARP抑制剂以外的卵巢癌治疗进展

卷 23, 期 6, 2023

发表于: 13 March, 2023

页: [433 - 446] 页: 14

弟呕挨: 10.2174/1568009623666230209121732

价格: $65

Open Access Journals Promotions 2
摘要

卵巢癌已成为妇科癌症相关死亡的最大原因。它通常在晚期才被诊断出来，并且没有有效的筛查策略。卵巢癌是一种高度异质性的疾病，可以细分为几个分子亚群。由于对涉及致癌作用和肿瘤生长的分子途径有了更深入的了解，靶向药物已经获得批准或处于几个开发阶段。聚（ADP-核糖）聚合酶（PARP）抑制剂和抗血管内皮生长因子（VEGF）-A抗体是目前获批最有效的两类卵巢癌靶向药物。随着贝伐珠单抗的成功，正在研究可以靶向替代血管生成途径的酪氨酸激酶抑制剂。此外，许多针对 PI3 激酶 （PI3K）/AKT/哺乳动物雷帕霉素靶标 （mTOR） 通路的治疗正在开发中或已经在临床研究中。微小RNA也已成为卵巢癌治疗和临床诊断的新型生物标志物。本文回顾了支持卵巢癌生长依赖性通路靶向的分子、临床前和临床证据，并评估了与 PARP 抑制剂以外的靶向治疗相关的当前数据。

关键词: 卵巢癌,血管生成抑制剂,EGFR抑制剂,PI3K抑制剂,AKT抑制剂,miRNA相关靶点。

« Previous Next »
图形摘要

[1]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Prat, J. New insights into ovarian cancer pathology. Ann. Oncol., 2012, 23(10)(Suppl. 10), x111-x117.
[http://dx.doi.org/10.1093/annonc/mds300] [PMID: 22987944]
[3]
Brett, M.R.; Brett, M.R.; Jennifer, B.P.; Thomas, A.S.; Jennifer, B.P.; Thomas, A.S. Epidemiology of ovarian cancer: a review. Cancer Biol. Med., 2017, 14(1), 9-32.
[http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0084] [PMID: 28443200]
[4]
Boussios, S.; Rassy, E.; Moschetta, M.; Ghose, A.; Adeleke, S.; Sanchez, E.; Sheriff, M.; Chargari, C.; Pavlidis, N. BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. Cancers (Basel), 2022, 14(16), 3888.
[http://dx.doi.org/10.3390/cancers14163888] [PMID: 36010882]
[5]
Pavlidis, N.; Rassy, E.; Vermorken, J.B.; Assi, T.; Kattan, J.; Boussios, S.; Smith-Gagen, J. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol., 2021, 75, 102045.
[http://dx.doi.org/10.1016/j.canep.2021.102045] [PMID: 34638085]
[6]
Ghose, A.; Gullapalli, S.V.N.; Chohan, N.; Bolina, A.; Moschetta, M.; Rassy, E.; Boussios, S. Applications of proteomics in ovarian cancer: Dawn of a new era. Proteomes, 2022, 10(2), 16.
[http://dx.doi.org/10.3390/proteomes10020016] [PMID: 35645374]
[7]
Cheung, A.; Shah, S.; Parker, J.; Soor, P.; Limbu, A.; Sheriff, M.; Boussios, S. Non-epithelial ovarian cancers: How much do we really know? Int. J. Environ. Res. Public Health, 2022, 19(3), 1106.
[http://dx.doi.org/10.3390/ijerph19031106] [PMID: 35162125]
[8]
Boussios, S.; Moschetta, M.; Zarkavelis, G.; Papadaki, A.; Kefas, A.; Tatsi, K. Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects. Crit. Rev. Oncol. Hematol., 2017, 120, 43-51.
[http://dx.doi.org/10.1016/j.critrevonc.2017.10.007] [PMID: 29198337]
[9]
Boussios, S.; Karathanasi, A.; Zakynthinakis-Kyriakou, N.; Tsiouris, A.K.; Chatziantoniou, A.A.; Kanellos, F.S.; Tatsi, K. Ovarian carcinosarcoma: Current developments and future perspectives. Crit. Rev. Oncol. Hematol., 2019, 134, 46-55.
[http://dx.doi.org/10.1016/j.critrevonc.2018.12.006] [PMID: 30771873]
[10]
Boussios, S.; Attygalle, A.; Hazell, S.; Moschetta, M.; McLachlan, J.; Okines, A.; Banerjee, S. Malignant ovarian germ cell tumors in postmenopausal patients: The royal marsden experience and literature review. Anticancer Res., 2015, 35(12), 6713-6722.
[PMID: 26637887]
[11]
Colombo, N.; Sessa, C.; du Bois, A.; Ledermann, J.; McCluggage, W.G.; McNeish, I.; Morice, P.; Pignata, S.; Ray-Coquard, I.; Vergote, I.; Baert, T.; Belaroussi, I.; Dashora, A.; Olbrecht, S.; Planchamp, F.; Querleu, D.; Baert, T.; Banerjee, S.; Belaroussi, I.; Blecharz, P.; Bruchim, I.; Cibula, D.; Colombo, N.; Concin, N.; Davidson, B.; Dashora, A.; Devouassoux-Shisheboran, M.; du Bois, A.; Ferrero, A.; Glasspool, R.; González-Martin, A.; Heinzelmann-Schwarz, V.; Joly, F.; Kim, J.W.; Kridelka, F.; Ledermann, J.; Lorusso, D.; Mahner, S.; McCluggage, W.G.; McNeish, I.; Mikami, M.; Mirza, M.R.; Morice, P.; Nicum, S.; Olbrecht, S.; O’Donnell, D.M.; Pautier, P.; Planchamp, F.; Pignata, S.; Querleu, D.; Ray-Coquard, I.; Rodolakis, A.; Sehouli, J.; Selcukbiricik, F.; Sessa, C.; Singh, N.; Tan, D.S.P.; Timmerman, D.; Tognon, G.; van der Velden, J.; Vergote, I.; Witteveen, P.O.; Zeimet, A.G. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol., 2019, 30(5), 672-705.
[http://dx.doi.org/10.1093/annonc/mdz062] [PMID: 31046081]
[12]
Doubeni, C.A.; Doubeni, A.R.; Myers, A.E. Diagnosis and management of ovarian cancer. Am. Fam. Physician, 2016, 93(11), 937-944.
[PMID: 27281838]
[13]
Gaona-Luviano, P.; Medina-Gaona, L.A.; Magaña-Pérez, K. Epidemiology of ovarian cancer. Chin. Clin. Oncol, 2020, 9(4), 47.
[http://dx.doi.org/10.21037/cco-20-34] [PMID: 32648448]
[14]
Shah, S.; Cheung, A.; Kutka, M.; Sheriff, M.; Boussios, S. Epithelial ovarian cancer: Providing evidence of predisposition genes. Int. J. Environ. Res. Public Health, 2022, 19(13), 8113.
[http://dx.doi.org/10.3390/ijerph19138113] [PMID: 35805770]
[15]
Boussios, S.; Rassy, E.; Shah, S.; Ioannidou, E.; Sheriff, M.; Pavlidis, N. Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. Expert Opin. Ther. Targets, 2021, 25(5), 329-333.
[http://dx.doi.org/10.1080/14728222.2021.1951226] [PMID: 34225539]
[16]
Boussios, S.; Mikropoulos, C.; Samartzis, E.; Karihtala, P.; Moschetta, M.; Sheriff, M.; Karathanasi, A.; Sadauskaite, A.; Rassy, E.; Pavlidis, N. Wise management of ovarian cancer: On the cutting edge. J. Pers. Med., 2020, 10(2), 41.
[http://dx.doi.org/10.3390/jpm10020041] [PMID: 32455595]
[17]
Boussios, S.; Karihtala, P.; Moschetta, M.; Abson, C.; Karathanasi, A.; Zakynthinakis-Kyriakou, N.; Ryan, J.E.; Sheriff, M.; Rassy, E.; Pavlidis, N. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest. New Drugs, 2020, 38(1), 181-193.
[http://dx.doi.org/10.1007/s10637-019-00867-4] [PMID: 31650446]
[18]
Querleu, D.; Planchamp, F.; Chiva, L.; Fotopoulou, C.; Barton, D.; Cibula, D.; Aletti, G.; Carinelli, S.; Creutzberg, C.; Davidson, B.; Harter, P.; Lundvall, L.; Marth, C.; Morice, P.; Rafii, A.; Ray-Coquard, I.; Rockall, A.; Sessa, C.; van der Zee, A.; Vergote, I.; duBois, A. European society of gynaecological oncology (ESGO) guidelines for ovarian cancer surgery. Int. J. Gynecol. Cancer, 2017, 27(7), 1534-1542.
[http://dx.doi.org/10.1097/IGC.0000000000001041] [PMID: 30814245]
[19]
Moschetta, M.; Boussios, S.; Rassy, E.; Samartzis, E.P.; Funingana, G.; Uccello, M. Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going? Ann. Transl. Med., 2020, 8(24), 1710.
[http://dx.doi.org/10.21037/atm-20-1683] [PMID: 33490222]
[20]
Boussios, S.; Moschetta, M.; Tatsi, K.; Tsiouris, A.K.; Pavlidis, N. A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives. J. Adv. Res., 2018, 12, 1-9.
[http://dx.doi.org/10.1016/j.jare.2018.02.006] [PMID: 29988841]
[21]
Boussios, S.; Abson, C.; Moschetta, M.; Rassy, E.; Karathanasi, A.; Bhat, T.; Ghumman, F.; Sheriff, M.; Pavlidis, N. Poly (ADP-Ribose) polymerase inhibitors: Talazoparib in ovarian cancer and beyond. Drugs R D., 2020, 20(2), 55-73.
[http://dx.doi.org/10.1007/s40268-020-00301-8] [PMID: 32215876]
[22]
Revythis, A.; Limbu, A.; Mikropoulos, C.; Ghose, A.; Sanchez, E.; Sheriff, M.; Boussios, S. Recent insights into PARP and immuno-checkpoint inhibitors in epithelial ovarian cancer. Int. J. Environ. Res. Public Health, 2022, 19(14), 8577.
[http://dx.doi.org/10.3390/ijerph19148577] [PMID: 35886427]
[23]
Pignata, S.C; Cecere, S.; Du Bois, A.; Harter, P.; Heitz, F. Treatment of recurrent ovarian cancer. Ann. Oncol., 2017, 28(8), viii51-viii56.
[http://dx.doi.org/10.1093/annonc/mdx441]
[24]
Grunewald, T.; Ledermann, J.A. Targeted therapies for ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol., 2017, 41, 139-152.
[http://dx.doi.org/10.1016/j.bpobgyn.2016.12.001] [PMID: 28111228]
[25]
Boussios, S.; Ozturk, M.; Moschetta, M.; Karathanasi, A.; Zakynthinakis-Kyriakou, N.; Katsanos, K.; Christodoulou, D.; Pavlidis, N. The developing story of predictive biomarkers in colorectal cancer. J. Pers. Med., 2019, 9(1), 12.
[http://dx.doi.org/10.3390/jpm9010012] [PMID: 30736475]
[26]
Revythis, A.; Shah, S.; Kutka, M.; Moschetta, M.; Ozturk, M.A.; Pappas-Gogos, G.; Ioannidou, E.; Sheriff, M.; Rassy, E.; Boussios, S. Unraveling the wide spectrum of melanoma biomarkers. Diagnostics (Basel), 2021, 11(8), 1341.
[http://dx.doi.org/10.3390/diagnostics11081341] [PMID: 34441278]
[27]
Saxby, H.; Mikropoulos, C.; Boussios, S. An update on the prognostic and predictive serum biomarkers in metastatic prostate cancer. Diagnostics, (Basel), 2020, 10(8), 549.
[28]
Cortez, A.J.; Tudrej, P.; Kujawa, K.A.; Lisowska, K.M. Advances in ovarian cancer therapy. Cancer Chemother. Pharmacol., 2018, 81(1), 17-38.
[http://dx.doi.org/10.1007/s00280-017-3501-8] [PMID: 29249039]
[29]
Ioannidou, E.; Moschetta, M.; Shah, S.; Parker, J.S.; Ozturk, M.A.; Pappas-Gogos, G.; Sheriff, M.; Rassy, E.; Boussios, S. Angiogenesis and anti-angiogenic treatment in prostate cancer: Mechanisms of action and molecular Targets. Int. J. Mol. Sci., 2021, 22(18), 9926.
[http://dx.doi.org/10.3390/ijms22189926] [PMID: 34576107]
[30]
McClung, E.C.; Wenham, R.M. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. Int. J. Womens Health, 2016, 8, 59-75.
[PMID: 27051317]
[31]
Kommoss, S.; Winterhoff, B.; Oberg, A.L.; Konecny, G.E.; Wang, C.; Riska, S.M.; Fan, J.B.; Maurer, M.J.; April, C.; Shridhar, V.; Kommoss, F.; du Bois, A.; Hilpert, F.; Mahner, S.; Baumann, K.; Schroeder, W.; Burges, A.; Canzler, U.; Chien, J.; Embleton, A.C.; Parmar, M.; Kaplan, R.; Perren, T.; Hartmann, L.C.; Goode, E.L.; Dowdy, S.C.; Pfisterer, J. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin. Cancer Res., 2017, 23(14), 3794-3801.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-2196] [PMID: 28159814]
[32]
Armstrong, D.K.; Alvarez, R.D.; Bakkum-Gamez, J.N.; Barroilhet, L.; Behbakht, K.; Berchuck, A.; Chen, L.; Cristea, M.; DeRosa, M.; Eisenhauer, E.L.; Gershenson, D.M.; Gray, H.J.; Grisham, R.; Hakam, A.; Jain, A.; Karam, A.; Konecny, G.E.; Leath, C.A.; Liu, J.; Mahdi, H.; Martin, L.; Matei, D.; McHale, M.; McLean, K.; Miller, D.S.; O’Malley, D.M.; Percac-Lima, S.; Ratner, E.; Remmenga, S.W.; Vargas, R.; Werner, T.L.; Zsiros, E.; Burns, J.L.; Engh, A.M. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw., 2021, 19(2), 191-226.
[http://dx.doi.org/10.6004/jnccn.2021.0007] [PMID: 33545690]
[33]
Burger, R.A.; Brady, M.F.; Bookman, M.A.; Fleming, G.F.; Monk, B.J.; Huang, H.; Mannel, R.S.; Homesley, H.D.; Fowler, J.; Greer, B.E.; Boente, M.; Birrer, M.J.; Liang, S.X. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med., 2011, 365(26), 2473-2483.
[http://dx.doi.org/10.1056/NEJMoa1104390] [PMID: 22204724]
[34]
Perren, T.J.; Swart, A.M.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; Kurzeder, C.; Bois, A.; Sehouli, J.; Kimmig, R.; Stähle, A.; Collinson, F.; Essapen, S.; Gourley, C.; Lortholary, A.; Selle, F.; Mirza, M.R.; Leminen, A.; Plante, M.; Stark, D.; Qian, W.; Parmar, M.K.B.; Oza, A.M. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med., 2011, 365(26), 2484-2496.
[http://dx.doi.org/10.1056/NEJMoa1103799] [PMID: 22204725]
[35]
Aghajanian, C.; Goff, B.; Nycum, L.R.; Wang, Y.V.; Husain, A.; Blank, S.V. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol. Oncol., 2015, 139(1), 10-16.
[http://dx.doi.org/10.1016/j.ygyno.2015.08.004] [PMID: 26271155]
[36]
Coleman, R.L.; Brady, M.F.; Herzog, T.J.; Sabbatini, P.; Armstrong, D.K.; Walker, J.L.; Kim, B.G.; Fujiwara, K.; Tewari, K.S.; O’Malley, D.M.; Davidson, S.A.; Rubin, S.C.; DiSilvestro, P.; Basen-Engquist, K.; Huang, H.; Chan, J.K.; Spirtos, N.M.; Ashfaq, R.; Mannel, R.S. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol., 2017, 18(6), 779-791.
[http://dx.doi.org/10.1016/S1470-2045(17)30279-6] [PMID: 28438473]
[37]
Pujade-Lauraine, E. New treatments in ovarian cancer. Ann. Oncol., 2017, 28(8), viii57-viii60.
[http://dx.doi.org/10.1093/annonc/mdx442]
[38]
Rouzier, R.; Gouy, S.; Selle, F.; Lambaudie, E.; Floquet, A.; Fourchotte, V.; Pomel, C.; Colombo, P.E.; Kalbacher, E.; Martin-Francoise, S.; Fauvet, R.; Follana, P.; Lesoin, A.; Lecuru, F.; Ghazi, Y.; Dupin, J.; Chereau, E.; Zohar, S.; Cottu, P.; Joly, F. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. Eur. J. Cancer, 2017, 70, 133-142.
[http://dx.doi.org/10.1016/j.ejca.2016.09.036] [PMID: 27914243]
[39]
Garcia Garcia, Y.; De Juan, A.; Mendiola, C.; Barretina-Ginesta, M.P.; Prat, A.; Santaballa, A.; Bover, I.; Gil-Martin, M.; Manzano, A.; Rubio, M.J.; Romeo, M.; Arqueros, C.; Garcia Martinez, E.; Gonzalez Martin, A. Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC)‏ (GEICO 1205/NOVA TRIAL). J. Clin. Oncol., 2017, 35(Suppl. 15), 5508.
[http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5508]
[40]
Tewari, K.S.; Burger, R.A.; Enserro, D.; Norquist, B.M.; Swisher, E.M.; Brady, M.F.; Bookman, M.A.; Fleming, G.F.; Huang, H.; Homesley, H.D.; Fowler, J.M.; Greer, B.E.; Boente, M.; Liang, S.X.; Ye, C.; Bais, C.; Randall, L.M.; Chan, J.K.; Ferriss, J.S.; Coleman, R.L.; Aghajanian, C.; Herzog, T.J.; DiSaia, P.J.; Copeland, L.J.; Mannel, R.S.; Birrer, M.J.; Monk, B.J. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian Cancer. J. Clin. Oncol., 2019, 37(26), 2317-2328.
[http://dx.doi.org/10.1200/JCO.19.01009] [PMID: 31216226]
[41]
Boussios, S.; Karathanasi, A.; Cooke, D.; Neille, C.; Sadauskaite, A.; Moschetta, M.; Zakynthinakis-Kyriakou, N.; Pavlidis, N. PARP inhibitors in ovarian cancer: The route to “Ithaca”. Diagnostics (Basel), 2019, 9(2), 55.
[http://dx.doi.org/10.3390/diagnostics9020055] [PMID: 31109041]
[42]
Ciombor, K.K.; Berlin, J.; Chan, E. Aflibercept. Clin. Cancer Res., 2013, 19(8), 1920-1925.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-2911] [PMID: 23444216]
[43]
Hu, L.; Hofmann, J.; Holash, J.; Yancopoulos, G.D.; Sood, A.K.; Jaffe, R.B. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res., 2005, 11(19), 6966-6971.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-0910] [PMID: 16203789]
[44]
Huang, J.; Hu, W.; Hu, L.; Previs, R.A.; Dalton, H.J.; Yang, X.Y.; Sun, Y.; McGuire, M.; Rupaimoole, R.; Nagaraja, A.S.; Kang, Y.; Liu, T.; Nick, A.M.; Jennings, N.B.; Coleman, R.L.; Jaffe, R.B.; Sood, A.K. Dll4 inhibition plus aflibercept markedly reduces ovarian tumor growth. Mol. Cancer Ther., 2016, 15(6), 1344-1352.
[http://dx.doi.org/10.1158/1535-7163.MCT-15-0144] [PMID: 27009216]
[45]
Chiorean, E.G.; LoRusso, P.; Strother, R.M.; Diamond, J.R.; Younger, A.; Messersmith, W.A.; Adriaens, L.; Liu, L.; Kao, R.J.; DiCioccio, A.T.; Kostic, A.; Leek, R.; Harris, A.; Jimeno, A. A Phase I First-in-human study of Enoticumab (REGN421), a fully human Delta-like Ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors. Clin. Cancer Res., 2015, 21(12), 2695-2703.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-2797] [PMID: 25724527]
[46]
Matulonis, U.A.; Berlin, S.; Ivy, P.; Tyburski, K.; Krasner, C.; Zarwan, C.; Berkenblit, A.; Campos, S.; Horowitz, N.; Cannistra, S.A.; Lee, H.; Lee, J.; Roche, M.; Hill, M.; Whalen, C.; Sullivan, L.; Tran, C.; Humphreys, B.D.; Penson, R.T. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J. Clin. Oncol., 2009, 27(33), 5601-5606.
[http://dx.doi.org/10.1200/JCO.2009.23.2777] [PMID: 19826113]
[47]
Tang, W.; McCormick, A.; Li, J.; Masson, E. Clinical pharmacokinetics and pharmacodynamics of Cediranib. Clin. Pharmacokinet., 2017, 56(7), 689-702.
[http://dx.doi.org/10.1007/s40262-016-0488-y] [PMID: 27943222]
[48]
Liu, J.F.; Barry, W.T.; Birrer, M.; Lee, J.M.; Buckanovich, R.J.; Fleming, G.F.; Rimel, B.J.; Buss, M.K.; Nattam, S.R.; Hurteau, J.; Luo, W.; Curtis, J.; Whalen, C.; Kohn, E.C.; Ivy, S.P.; Matulonis, U.A. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann. Oncol., 2019, 30(4), 551-557.
[http://dx.doi.org/10.1093/annonc/mdz018] [PMID: 30753272]
[49]
Hamberg, P.; Verweij, J.; Sleijfer, S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist, 2010, 15(6), 539-547.
[http://dx.doi.org/10.1634/theoncologist.2009-0274] [PMID: 20511320]
[50]
McLachlan, J.; Banerjee, S. Pazopanib in ovarian cancer. Expert Rev. Anticancer Ther., 2015, 15(9), 995-1005.
[http://dx.doi.org/10.1586/14737140.2015.1081383] [PMID: 26296187]
[51]
Richardson, D.L.; Sill, M.W.; Coleman, R.L.; Sood, A.K.; Pearl, M.L.; Kehoe, S.M.; Carney, M.E.; Hanjani, P.; Van Le, L.; Zhou, X.C.; Alvarez Secord, A.; Gray, H.J.; Landrum, L.M.; Lankes, H.A.; Hu, W.; Aghajanian, C. Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer. JAMA Oncol., 2018, 4(2), 196-202.
[http://dx.doi.org/10.1001/jamaoncol.2017.4218] [PMID: 29242937]
[52]
Roth, G.J.; Binder, R.; Colbatzky, F.; Dallinger, C.; Schlenker-Herceg, R.; Hilberg, F.; Wollin, S.L.; Kaiser, R. Nintedanib: from discovery to the clinic. J. Med. Chem., 2015, 58(3), 1053-1063.
[http://dx.doi.org/10.1021/jm501562a] [PMID: 25474320]
[53]
McCormack, P.L. Nintedanib: first global approval. Drugs, 2015, 75(1), 129-139.
[http://dx.doi.org/10.1007/s40265-014-0335-0] [PMID: 25430078]
[54]
Secord, A.A.; McCollum, M.; Davidson, B.A.; Broadwater, G.; Squatrito, R.; Havrilesky, L.J.; Gabel, A.C.; Starr, M.D.; Brady, J.C.; Nixon, A.B.; Duska, L.R. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. Gynecol. Oncol., 2019, 153(3), 555-561.
[http://dx.doi.org/10.1016/j.ygyno.2019.03.246] [PMID: 30929823]
[55]
du Bois, A.; Floquet, A.; Kim, J.W.; Rau, J.; del Campo, J.M.; Friedlander, M.; Pignata, S.; Fujiwara, K.; Vergote, I.; Colombo, N.; Mirza, M.R.; Monk, B.J.; Kimmig, R.; Ray-Coquard, I.; Zang, R.; Diaz-Padilla, I.; Baumann, K.H.; Mouret-Reynier, M.A.; Kim, J.H.; Kurzeder, C.; Lesoin, A.; Vasey, P.; Marth, C.; Canzler, U.; Scambia, G.; Shimada, M.; Calvert, P.; Pujade-Lauraine, E.; Kim, B.G.; Herzog, T.J.; Mitrica, I.; Schade-Brittinger, C.; Wang, Q.; Crescenzo, R.; Harter, P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J. Clin. Oncol., 2014, 32(30), 3374-3382.
[http://dx.doi.org/10.1200/JCO.2014.55.7348] [PMID: 25225436]
[56]
Dinkic, C.; Eichbaum, M.; Schmidt, M.; Grischke, E.M.; Gebauer, G.; Fricke, H.C.; Lenz, F.; Wallwiener, M.; Marme, F.; Schneeweiss, A.; Sohn, C.; Rom, J. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. Gynecol. Oncol., 2017, 146(2), 279-284.
[http://dx.doi.org/10.1016/j.ygyno.2017.05.013] [PMID: 28528917]
[57]
Stark, D.P.; Cook, A.; Brown, J.M.; Brundage, M.D.; Embleton, A.C.; Kaplan, R.S.; Raja, F.A.; Swart, A.M.W.; Velikova, G.; Qian, W.; Ledermann, J.A. Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial. Cancer, 2017, 123(14), 2752-2761.
[http://dx.doi.org/10.1002/cncr.30657] [PMID: 28339098]
[58]
Ray-Coquard, I.; Cibula, D.; Mirza, M.R.; Reuss, A.; Ricci, C.; Colombo, N.; Koch, H.; Goffin, F.; González-Martin, A.; Ottevanger, P.B.; Baumann, K.; Bjørge, L.; Lesoin, A.; Burges, A.; Rosenberg, P.; Gropp-Meier, M.; Harrela, M.; Harter, P.; Frenel, J.S.; Minarik, T.; Pisano, C.; Hasenburg, A.; Merger, M.; Bois, A. Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. Int. J. Cancer, 2020, 146(2), 439-448.
[http://dx.doi.org/10.1002/ijc.32606] [PMID: 31381147]
[59]
Dufraine, J.; Funahashi, Y.; Kitajewski, J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene, 2008, 27(38), 5132-5137.
[http://dx.doi.org/10.1038/onc.2008.227] [PMID: 18758482]
[60]
Xie, Q.; Cheng, Z.; Chen, X.; Lobe, C.G.; Liu, J. The role of Notch signalling in ovarian angiogenesis. J. Ovarian Res., 2017, 10(1), 13.
[http://dx.doi.org/10.1186/s13048-017-0308-5] [PMID: 28284219]
[61]
Perez-Fidalgo, J.A.; Ortega, B.; Simon, S.; Samartzis, E.P.; Boussios, S. NOTCH signalling in ovarian cancer angiogenesis. Ann. Transl. Med., 2020, 8(24), 1705.
[http://dx.doi.org/10.21037/atm-20-4497] [PMID: 33490217]
[62]
Hu, W.; Lu, C.; Dong, H.H.; Huang, J.; Shen, D.; Stone, R.L.; Nick, A.M.; Shahzad, M.M.K.; Mora, E.; Jennings, N.B.; Lee, S.J.; Roh, J.W.; Matsuo, K.; Nishimura, M.; Goodman, B.W.; Jaffe, R.B.; Langley, R.R.; Deavers, M.T.; Lopez-Berestein, G.; Coleman, R.L.; Sood, A.K. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res., 2011, 71(18), 6030-6039.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-2719] [PMID: 21795478]
[63]
Feng, Z.; Xu, W.; Zhang, C.; Liu, M.; Wen, H. Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer. Oncotarget, 2017, 8(5), 8215-8225.
[http://dx.doi.org/10.18632/oncotarget.14152] [PMID: 28030808]
[64]
McCaw, T.R.; Inga, E.; Chen, H.; Jaskula-Sztul, R.; Dudeja, V.; Bibb, J.A.; Ren, B.; Rose, J.B. Gamma Secretase inhibitors in cancer: A current perspective on clinical performance. Oncologist, 2021, 26(4), e608-e621.
[http://dx.doi.org/10.1002/onco.13627] [PMID: 33284507]
[65]
Shah, M.M.; Zerlin, M.; Li, B.Y.; Herzog, T.J.; Kitajewski, J.K.; Wright, J.D. The role of Notch and gamma-secretase inhibition in an ovarian cancer model. Anticancer Res., 2013, 33(3), 801-808.
[PMID: 23482747]
[66]
Kuhnert, F.; Chen, G.; Coetzee, S.; Thambi, N.; Hickey, C.; Shan, J.; Kovalenko, P.; Noguera-Troise, I.; Smith, E.; Fairhurst, J.; Andreev, J.; Kirshner, J.R.; Papadopoulos, N.; Thurston, G. Dll4 blockade in stromal cells mediates antitumor effects in preclinical models of ovarian cancer. Cancer Res., 2015, 75(19), 4086-4096.
[http://dx.doi.org/10.1158/0008-5472.CAN-14-3773] [PMID: 26377940]
[67]
Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther., 1999, 82(2-3), 195-206.
[http://dx.doi.org/10.1016/S0163-7258(98)00044-8] [PMID: 10454197]
[68]
Mubeen, M.; Kini, S.G. A review on: The design and development of EGFR tyrosine kinase inhibitors in cancer therapy. Int. J. Ther. Appl., 2012, 5, 29-37.
[69]
Katopodis, P.; Chudasama, D.; Wander, G.; Sales, L.; Kumar, J.; Pandhal, M.; Anikin, V.; Chatterjee, J.; Hall, M.; Karteris, E. Kinase inhibitors and ovarian cancer. Cancers (Basel), 2019, 11(9), 1357.
[http://dx.doi.org/10.3390/cancers11091357] [PMID: 31547471]
[70]
Bareschino, M.A.; Schettino, C.; Troiani, T.; Martinelli, E.; Morgillo, F.; Ciardiello, F. Erlotinib in cancer treatment. Ann. Oncol., 2007, 18(6)(Suppl. 6), vi35-vi41.
[http://dx.doi.org/10.1093/annonc/mdm222] [PMID: 17591829]
[71]
Blank, S.V.; Christos, P.; Curtin, J.P.; Goldman, N.; Runowicz, C.D.; Sparano, J.A.; Liebes, L.; Chen, H.X.; Muggia, F.M. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment. Gynecol. Oncol., 2010, 119(3), 451-456.
[http://dx.doi.org/10.1016/j.ygyno.2010.08.008] [PMID: 20837357]
[72]
Vergote, I.B.; Jimeno, A.; Joly, F.; Katsaros, D.; Coens, C.; Despierre, E.; Marth, C.; Hall, M.; Steer, C.B.; Colombo, N.; Lesoin, A.; Casado, A.; Reinthaller, A.; Green, J.; Buck, M.; Ray-Coquard, I.; Ferrero, A.; Favier, L.; Reed, N.S.; Curé, H.; Pujade-Lauraine, E. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J. Clin. Oncol., 2014, 32(4), 320-326.
[http://dx.doi.org/10.1200/JCO.2013.50.5669] [PMID: 24366937]
[73]
Sanford, M.; Scott, L.J. Gefitinib. Drugs, 2009, 69(16), 2303-2328.
[http://dx.doi.org/10.2165/10489100-000000000-00000] [PMID: 19852530]
[74]
Cohen, M.H.; Williams, G.A.; Sridhara, R.; Chen, G.; Pazdur, R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist, 2003, 8(4), 303-306.
[http://dx.doi.org/10.1634/theoncologist.8-4-303] [PMID: 12897327]
[75]
Thibault, B.; Jean-Claude, B. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells. J. Ovarian Res., 2017, 10(1), 31.
[http://dx.doi.org/10.1186/s13048-017-0319-2] [PMID: 28446239]
[76]
Medina, P.; Goodin, S. Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther., 2008, 30(8), 1426-1447.
[http://dx.doi.org/10.1016/j.clinthera.2008.08.008] [PMID: 18803986]
[77]
Moy, B.; Kirkpatrick, P.; Kar, S.; Goss, P. Lapatinib. Nat. Rev. Drug Discov., 2007, 6(6), 431-432.
[http://dx.doi.org/10.1038/nrd2332] [PMID: 17633789]
[78]
Yang, Y.; Zhang, H.; Chen, W.; Chen, X.; Yu, X. Lapatinib promotes ovarian cancer cell apoptosis through mROS-HtrA2/Omi pathways. Eur. J. Gynaecol. Oncol., 2020, 41(4), 598-603.
[http://dx.doi.org/10.31083/j.ejgo.2020.04.5247]
[79]
McCorkle, R.; Gorski, J.W.; Anderson, A.; Kolesar, J.M. Abstract A50: Lapatinib potentiates the antitumor effects of paclitaxel treatment in resistant ovarian cancer cells. Clin. Cancer Res., 2020, 26(13)(Supplement.), A50.
[http://dx.doi.org/10.1158/1557-3265.OVCA19-A50]
[80]
Dienstmann, R.; Rodon, J.; Serra, V.; Tabernero, J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol. Cancer Ther., 2014, 13(5), 1021-1031.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0639] [PMID: 24748656]
[81]
Huang, T.T.; Lampert, E.J.; Coots, C.; Lee, J.M. Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer. Cancer Treat. Rev., 2020, 86, 102021.
[http://dx.doi.org/10.1016/j.ctrv.2020.102021] [PMID: 32311593]
[82]
Dobbin, Z.; Landen, C. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int. J. Mol. Sci., 2013, 14(4), 8213-8227.
[http://dx.doi.org/10.3390/ijms14048213] [PMID: 23591839]
[83]
van der Ploeg, P.; Uittenboogaard, A.; Thijs, A.M.J.; Westgeest, H.M.; Boere, I.A.; Lambrechts, S.; van de Stolpe, A.; Bekkers, R.L.M.; Piek, J.M.J. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis. Gynecol. Oncol., 2021, 163(2), 433-444.
[http://dx.doi.org/10.1016/j.ygyno.2021.07.008] [PMID: 34253390]
[84]
Hong, D.S.; Bowles, D.W.; Falchook, G.S.; Messersmith, W.A.; George, G.C.; O’Bryant, C.L.; Vo, A.C.H.; Klucher, K.; Herbst, R.S.; Eckhardt, S.G.; Peterson, S.; Hausman, D.F.; Kurzrock, R.; Jimeno, A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res., 2012, 18(15), 4173-4182.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-0714] [PMID: 22693357]
[85]
Hu, L.; Zaloudek, C.; Mills, G.B.; Gray, J.; Jaffe, R.B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res., 2000, 6(3), 880-886.
[PMID: 10741711]
[86]
Bedard, P.L.; Tabernero, J.; Janku, F.; Wainberg, Z.A.; Paz-Ares, L.; Vansteenkiste, J.; Van Cutsem, E.; Pérez-García, J.; Stathis, A.; Britten, C.D.; Le, N.; Carter, K.; Demanse, D.; Csonka, D.; Peters, M.; Zubel, A.; Nauwelaerts, H.; Sessa, C. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin. Cancer Res., 2015, 21(4), 730-738.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-1814] [PMID: 25500057]
[87]
Nitulescu, G.M.; Margina, D.; Juzenas, P.; Peng, Q.; Olaru, O.T.; Saloustros, E.; Fenga, C.; Spandidos, D.A.; Libra, M.; Tsatsakis, A.M. Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). Int. J. Oncol., 2016, 48(3), 869-885.
[http://dx.doi.org/10.3892/ijo.2015.3306] [PMID: 26698230]
[88]
Brown, J.S.; Banerji, U. Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol. Ther., 2017, 172, 101-115.
[http://dx.doi.org/10.1016/j.pharmthera.2016.12.001] [PMID: 27919797]
[89]
Fu, S.; Hennessy, B.T.; Ng, C.S.; Ju, Z.; Coombes, K.R.; Wolf, J.K.; Sood, A.K.; Levenback, C.F.; Coleman, R.L.; Kavanagh, J.J.; Gershenson, D.M.; Markman, M.; Dice, K.; Howard, A.; Li, J.; Li, Y.; Stemke-Hale, K.; Dyer, M.; Atkinson, E.; Jackson, E.; Kundra, V.; Kurzrock, R.; Bast, R.C., Jr; Mills, G.B. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol. Oncol., 2012, 126(1), 47-53.
[http://dx.doi.org/10.1016/j.ygyno.2012.04.006] [PMID: 22487539]
[90]
Hu, X.; Xia, M.; Wang, J.; Yu, H.; Chai, J.; Zhang, Z.; Sun, Y.; Su, J.; Sun, L. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy. Biomed. Pharmacother., 2020, 129, 110397.
[http://dx.doi.org/10.1016/j.biopha.2020.110397] [PMID: 32585451]
[91]
Choi, H.J.; Heo, J.H.; Park, J.Y.; Jeong, J.Y.; Cho, H.J.; Park, K.S.; Kim, S.H.; Moon, Y.W.; Kim, J.S.; An, H.J. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer. Gynecol. Oncol., 2019, 153(1), 135-148.
[http://dx.doi.org/10.1016/j.ygyno.2019.01.012] [PMID: 30686552]
[92]
Urpilainen, E.; Puistola, U.; Boussios, S.; Karihtala, P. Metformin and ovarian cancer: the evidence. Ann. Transl. Med., 2020, 8(24), 1711.
[http://dx.doi.org/10.21037/atm-20-1060] [PMID: 33490223]
[93]
Tang, G.; Guo, J.; Zhu, Y.; Huang, Z.; Liu, T.; Cai, J.; Yu, L.; Wang, Z. Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation. Int. J. Oncol., 2018, 52(6), 1899-1911.
[http://dx.doi.org/10.3892/ijo.2018.4343] [PMID: 29620187]
[94]
Brown, J.R.; Chan, D.K.; Shank, J.J.; Griffith, K.A.; Fan, H.; Szulawski, R.; Yang, K.; Reynolds, R.K.; Johnston, C.; McLean, K.; Uppal, S.; Liu, J.R.; Cabrera, L.; Taylor, S.E.; Orr, B.C.; Modugno, F.; Mehta, P.; Bregenzer, M.; Mehta, G.; Shen, H.; Coffman, L.; Buckanovich, R.J. Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight, 2020, 5(11), e133247.
[http://dx.doi.org/10.1172/jci.insight.133247] [PMID: 32369446]
[95]
Wu, B.; Li, S.; Sheng, L.; Zhu, J.; Gu, L.; Shen, H.; La, D.; Hambly, B.D.; Bao, S.; Di, W. Metformin inhibits the development and metastasis of ovarian cancer. Oncol. Rep., 2012, 28(3), 903-908.
[http://dx.doi.org/10.3892/or.2012.1890] [PMID: 22752027]
[96]
Kinose, Y.; Sawada, K.; Nakamura, K.; Kimura, T. The role of microRNAs in ovarian cancer. BioMed Res. Int., 2014, 2014, 249393.
[http://dx.doi.org/10.1155/2014/249393] [PMID: 25295252]
[97]
Chen, S.N.; Chang, R.; Lin, L.T.; Chern, C.U.; Tsai, H.W.; Wen, Z.H.; Li, Y.H.; Li, C.J.; Tsui, K.H. MicroRNA in ovarian cancer: Biology, pathogenesis, and therapeutic opportunities. Int. J. Environ. Res. Public Health, 2019, 16(9), 1510.
[http://dx.doi.org/10.3390/ijerph16091510] [PMID: 31035447]
[98]
Zaman, M.S.; Maher, D.M.; Khan, S.; Jaggi, M.; Chauhan, S.C. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J. Ovarian Res., 2012, 5(1), 44.
[http://dx.doi.org/10.1186/1757-2215-5-44] [PMID: 23237306]
[99]
Zhang, L.; Huang, J.; Yang, N.; Greshock, J.; Megraw, M.S.; Giannakakis, A.; Liang, S.; Naylor, T.L.; Barchetti, A.; Ward, M.R.; Yao, G.; Medina, A.; O’Brien-Jenkins, A.; Katsaros, D.; Hatzigeorgiou, A.; Gimotty, P.A.; Weber, B.L.; Coukos, G. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. USA, 2006, 103(24), 9136-9141.
[http://dx.doi.org/10.1073/pnas.0508889103] [PMID: 16754881]
[100]
Iorio, M.V.; Visone, R.; Di Leva, G.; Donati, V.; Petrocca, F.; Casalini, P.; Taccioli, C.; Volinia, S.; Liu, C.G.; Alder, H.; Calin, G.A.; Ménard, S.; Croce, C.M. MicroRNA signatures in human ovarian cancer. Cancer Res., 2007, 67(18), 8699-8707.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-1936] [PMID: 17875710]
[101]
Zhang, S.; Lu, Z.; Unruh, A.K.; Ivan, C.; Baggerly, K.A.; Calin, G.A.; Li, Z.; Bast, R.C., Jr; Le, X.F. Clinically relevant microRNAs in ovarian cancer. Mol. Cancer Res., 2015, 13(3), 393-401.
[http://dx.doi.org/10.1158/1541-7786.MCR-14-0424] [PMID: 25304686]
[102]
Zhang, L.; Conejo-Garcia, J.R.; Katsaros, D.; Gimotty, P.A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M.N.; Rubin, S.C.; Coukos, G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med., 2003, 348(3), 203-213.
[http://dx.doi.org/10.1056/NEJMoa020177] [PMID: 12529460]
[103]
Sadelain, M.; Rivière, I.; Riddell, S. Therapeutic T cell engineering. Nature, 2017, 545(7655), 423-431.
[http://dx.doi.org/10.1038/nature22395] [PMID: 28541315]
[104]
Rezvani, K.; Rouce, R.; Liu, E.; Shpall, E. Engineering natural killer cells for cancer immunotherapy. Mol. Ther., 2017, 25(8), 1769-1781.
[http://dx.doi.org/10.1016/j.ymthe.2017.06.012] [PMID: 28668320]
[105]
Pang, Z.; Wang, Z.; Li, F.; Feng, C.; Mu, X. Current progress of CAR-NK therapy in cancer treatment. Cancers (Basel), 2022, 14(17), 4318.
[http://dx.doi.org/10.3390/cancers14174318] [PMID: 36077853]
[106]
Albinger, N.; Hartmann, J.; Ullrich, E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther., 2021, 28(9), 513-527.
[http://dx.doi.org/10.1038/s41434-021-00246-w] [PMID: 33753909]
[107]
Ebrahimiyan, H.; Tamimi, A.; Shokoohian, B.; Minaei, N.; Memarnejadian, A.; Hossein-Khannazer, N.; Hassan, M.; Vosough, M. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. Int. Immunopharmacol., 2022, 106, 108587.
[http://dx.doi.org/10.1016/j.intimp.2022.108587] [PMID: 35149294]
[108]
Hombach, A.; Hombach, A.A.; Abken, H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response. Gene Ther., 2010, 17(10), 1206-1213.
[http://dx.doi.org/10.1038/gt.2010.91] [PMID: 20555360]
[109]
Hudecek, M.; Sommermeyer, D.; Kosasih, P.L.; Silva-Benedict, A.; Liu, L.; Rader, C.; Jensen, M.C.; Riddell, S.R. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res., 2015, 3(2), 125-135.
[http://dx.doi.org/10.1158/2326-6066.CIR-14-0127] [PMID: 25212991]
[110]
Cao, B.; Liu, M.; Wang, L.; Liang, B.; Feng, Y.; Chen, X.; Shi, Y.; Zhang, J.; Ye, X.; Tian, Y.; Zhi, C.; Li, J.; Lian, H.; Wu, Q.; Zhang, Z. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer. Biochem. Biophys. Res. Commun., 2020, 524(1), 96-102.
[http://dx.doi.org/10.1016/j.bbrc.2020.01.053] [PMID: 31980173]
[111]
Ao, X.; Yang, Y.; Li, W.; Tan, Y.; Guo, W.; Ao, L.; He, X.; Wu, X.; Xia, J.; Xu, X.; Guo, J. Anti-αFR CAR-engineered NK-92 cellsdisplay potent cytotoxicity against αFR-positive ovarian cancer J.Immunother., 2019, 42(8), 284-296.
[http://dx.doi.org/10.1097/CJI.0000000000000286] [PMID: 31261167]
[112]
Zhu, X.; Cai, H.; Zhao, L.; Ning, L.; Lang, J. CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget,. 2017, 8(38), 64607-64621.
[http://dx.doi.org/10.18632/oncotarget.19929] [PMID: 28969098]

Rights & Permissions Print Cite
Article Metrics
96
2
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy